Venus Remedies Ltd.

NSE: VENUSREM | BSE: 526953

Value Stock, Under Radar

Download real time

290.40 -0.35 (-0.12%)

32.13% Fall from 52W High

23,652 NSE+BSE Volume

NSE 13 Mar, 2025 3:31 PM (IST)

388.2

Market Cap

Below industry Median

0.9

Beta 1Year

Low volatility

Venus Remedies Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Venus Remedies Ltd. on BSE

Search Inside the pdf :

Venus Remedies Ltd.

25 Feb 2025

290.40

-0.12%

Company Update

VENUS REMEDIES LTD. - 526953 - Venus Remedies Secures Exclusive In-Licensing Rights From Infex Therapeutics To …

BSE India

Venus Remedies secures exclusive In-Licensing rights from Infex Therapeutics to develop and commercialize MET-X in India

Venus Remedies Ltd.

10 Feb 2025

290.40

-0.12%

Company Update

VENUS REMEDIES LTD. - 526953 - Venus Remedies Gets Market Authorization For Anticoagulant Enoxaparin From Indonesia

BSE India

Venus Remedies gets Market Authorization for anticoagulant Enoxaparin from Indonesia

Venus Remedies Ltd.

06 Feb 2025

290.40

-0.12%

Company Update

VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

UFR News paper publication.

Venus Remedies Ltd.

05 Feb 2025

290.40

-0.12%

Corp. Note

VENUS REMEDIES LTD. - 526953 - Integrated Filing (Financial)

BSE India

Integrated filing of Unaudited Financial results for the period ended on 31st December 2024.

Venus Remedies Ltd.

04 Feb 2025

290.40

-0.12%

Company Update

VENUS REMEDIES LTD. - 526953 - Intimation Under Regulation 30

BSE India

Intimation under Regulation 30

Venus Remedies Ltd.

04 Feb 2025

290.40

-0.12%

Result

VENUS REMEDIES LTD. - 526953 - Unaudited Financial Results As On 31.12.2024

BSE India

Unaudited financial results as on 31.12.2024

	Dec 2024	Sep 2024	Dec 2023	Change QoQ%	Change YoY%
Total Revenue Qtr	178.89	178.03	145.77	0.5%	22.7%
Operating Profit Qtr	18.36	4.92	12.04	273.2%	52.5%
Net Profit Qtr	19.60	3.52	6.85	456.8%	186.1%
Earning Per Share Adjusted latest Qtr	14.66	2.63	5.12	457.4%	186.3%

* Consolidated data

Detailed Results

Venus Remedies Ltd.

04 Feb 2025

290.40

-0.12%

Board Meeting

VENUS REMEDIES LTD. - 526953 - Board Meeting Outcome for Outcome Of Board Meeting

BSE India

This has reference to the meeting of Board of Directors held on 4th February 2025 inter alia considered and approved: 1. Unaudited Financial Results for the quarter and nine months ended on 31st December 2024 along with Limited Review report. 2. The Board of Directors of the Company, based on a legal opinion, has resolved to write off the time-barred unsecured Foreign Currency Convertible Bond (FCCB) liability of ?38.68 crores including interest, which has remained unclaimed for over 10 years and is no longer legally enforceable under applicable laws.

Venus Remedies Ltd.

24 Jan 2025

290.40

-0.12%

Board Meeting

VENUS REMEDIES LTD. - 526953 - Board Meeting Intimation for Board Meeting Scheduled To Be Held …

BSE India

VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2025 ,inter alia, to consider and approve Board meeting scheduled to be held on 04th February 2025

Venus Remedies Ltd.

20 Jan 2025

290.40

-0.12%

Company Update

VENUS REMEDIES LTD. - 526953 - Venus Remedies Limited Successfully Renews EU GMP

BSE India

Venus Remedies Limited successfully renews EU GMP

Venus Remedies Ltd.

07 Jan 2025

290.40

-0.12%

Company Update

VENUS REMEDIES LTD. - 526953 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Compliance under reg 74(5) of SEBI DP regulations.

Is Venus Remedies Ltd. worth buying?

65 Votes:

Buy 73.85%

Sell 16.92%

Hold 9.23%